| Dr Fernando Hernandez, MD | |
|
7243 Della Dr Fl 3, Orlando, FL 32819-5104 | |
| (407) 370-8705 | |
| Not Available |
| Full Name | Dr Fernando Hernandez |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Location | 7243 Della Dr Fl 3, Orlando, Florida |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003886953 | NPI | - | NPPES |
| 039391600 | Medicaid | FL | |
| ME35823 | Other | FL | MEDICAL LICENSE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | ME35823 (Florida) | Primary |
| Entity Name | Physician Associates Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1336137280 PECOS PAC ID: 0244135093 Enrollment ID: O20031204000591 |
News Archive
Baxter International Inc. today announced the commercial launch of GLASSIATM [Alpha1-Proteinase Inhibitor (Human)] in the United States. GLASSIATM is the first available ready-to-use liquid alpha1-proteinase inhibitor (Alpha1-PI) and is indicated as a chronic augmentation and maintenance therapy in adults with emphysema due to congenital deficiency of alpha-1 antitrypsin (AAT), an under-diagnosed hereditary condition characterized by a low level of alpha-1 protein in the blood.
Senate Finance Committee Chairman Max Baucus, D-Mont., says that a comprehensive health reform package - due out from his committee within the next week or two - will include plans to compare the effectiveness of drugs and other medical treatments so Americans can answer the question: "What are we getting for our money?"
The authorization committee of the German Research Foundation (DFG) has approved funding for a collaborative research center proposed by the University of Freiburg on the topic „Control of Cell Motility in Morphogenesis, Tumor Invasion, and Metastatic Spread" starting on 1 January 2010. The Freiburg SFB 850 will receive a total of 9.4 million euros in the next four years plus a 20 percent program allowance for indirect costs. In the case of success, the SFB 850 is eligible to receive funding for up to 12 years.
In California, 900,000 people are still awaiting final processing of their Medicaid applications. Meanwhile, the impasse over the budget and Medicaid expansion continues in Virginia and The Washington Post reports that Gov. Terry McAuliffe is examining legal strategies to make the move without legislative approval.
A UT Southwestern Medical Center study to evaluate nursing protocols designed to better triage and treat stroke patients using telemedicine will be the first study using a new consortium of medical centers.
› Verified 1 days ago
| Entity Name | Orlando Health Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669429577 PECOS PAC ID: 9537059084 Enrollment ID: O20040318000044 |
News Archive
Baxter International Inc. today announced the commercial launch of GLASSIATM [Alpha1-Proteinase Inhibitor (Human)] in the United States. GLASSIATM is the first available ready-to-use liquid alpha1-proteinase inhibitor (Alpha1-PI) and is indicated as a chronic augmentation and maintenance therapy in adults with emphysema due to congenital deficiency of alpha-1 antitrypsin (AAT), an under-diagnosed hereditary condition characterized by a low level of alpha-1 protein in the blood.
Senate Finance Committee Chairman Max Baucus, D-Mont., says that a comprehensive health reform package - due out from his committee within the next week or two - will include plans to compare the effectiveness of drugs and other medical treatments so Americans can answer the question: "What are we getting for our money?"
The authorization committee of the German Research Foundation (DFG) has approved funding for a collaborative research center proposed by the University of Freiburg on the topic „Control of Cell Motility in Morphogenesis, Tumor Invasion, and Metastatic Spread" starting on 1 January 2010. The Freiburg SFB 850 will receive a total of 9.4 million euros in the next four years plus a 20 percent program allowance for indirect costs. In the case of success, the SFB 850 is eligible to receive funding for up to 12 years.
In California, 900,000 people are still awaiting final processing of their Medicaid applications. Meanwhile, the impasse over the budget and Medicaid expansion continues in Virginia and The Washington Post reports that Gov. Terry McAuliffe is examining legal strategies to make the move without legislative approval.
A UT Southwestern Medical Center study to evaluate nursing protocols designed to better triage and treat stroke patients using telemedicine will be the first study using a new consortium of medical centers.
› Verified 1 days ago
| Entity Name | Orlando Physicians Network Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568693554 PECOS PAC ID: 7719026251 Enrollment ID: O20091123000506 |
News Archive
Baxter International Inc. today announced the commercial launch of GLASSIATM [Alpha1-Proteinase Inhibitor (Human)] in the United States. GLASSIATM is the first available ready-to-use liquid alpha1-proteinase inhibitor (Alpha1-PI) and is indicated as a chronic augmentation and maintenance therapy in adults with emphysema due to congenital deficiency of alpha-1 antitrypsin (AAT), an under-diagnosed hereditary condition characterized by a low level of alpha-1 protein in the blood.
Senate Finance Committee Chairman Max Baucus, D-Mont., says that a comprehensive health reform package - due out from his committee within the next week or two - will include plans to compare the effectiveness of drugs and other medical treatments so Americans can answer the question: "What are we getting for our money?"
The authorization committee of the German Research Foundation (DFG) has approved funding for a collaborative research center proposed by the University of Freiburg on the topic „Control of Cell Motility in Morphogenesis, Tumor Invasion, and Metastatic Spread" starting on 1 January 2010. The Freiburg SFB 850 will receive a total of 9.4 million euros in the next four years plus a 20 percent program allowance for indirect costs. In the case of success, the SFB 850 is eligible to receive funding for up to 12 years.
In California, 900,000 people are still awaiting final processing of their Medicaid applications. Meanwhile, the impasse over the budget and Medicaid expansion continues in Virginia and The Washington Post reports that Gov. Terry McAuliffe is examining legal strategies to make the move without legislative approval.
A UT Southwestern Medical Center study to evaluate nursing protocols designed to better triage and treat stroke patients using telemedicine will be the first study using a new consortium of medical centers.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Fernando Hernandez, MD 7243 Della Dr Fl 3, Orlando, FL 32819-5104 Ph: () - | Dr Fernando Hernandez, MD 7243 Della Dr Fl 3, Orlando, FL 32819-5104 Ph: (407) 370-8705 |
News Archive
Baxter International Inc. today announced the commercial launch of GLASSIATM [Alpha1-Proteinase Inhibitor (Human)] in the United States. GLASSIATM is the first available ready-to-use liquid alpha1-proteinase inhibitor (Alpha1-PI) and is indicated as a chronic augmentation and maintenance therapy in adults with emphysema due to congenital deficiency of alpha-1 antitrypsin (AAT), an under-diagnosed hereditary condition characterized by a low level of alpha-1 protein in the blood.
Senate Finance Committee Chairman Max Baucus, D-Mont., says that a comprehensive health reform package - due out from his committee within the next week or two - will include plans to compare the effectiveness of drugs and other medical treatments so Americans can answer the question: "What are we getting for our money?"
The authorization committee of the German Research Foundation (DFG) has approved funding for a collaborative research center proposed by the University of Freiburg on the topic „Control of Cell Motility in Morphogenesis, Tumor Invasion, and Metastatic Spread" starting on 1 January 2010. The Freiburg SFB 850 will receive a total of 9.4 million euros in the next four years plus a 20 percent program allowance for indirect costs. In the case of success, the SFB 850 is eligible to receive funding for up to 12 years.
In California, 900,000 people are still awaiting final processing of their Medicaid applications. Meanwhile, the impasse over the budget and Medicaid expansion continues in Virginia and The Washington Post reports that Gov. Terry McAuliffe is examining legal strategies to make the move without legislative approval.
A UT Southwestern Medical Center study to evaluate nursing protocols designed to better triage and treat stroke patients using telemedicine will be the first study using a new consortium of medical centers.
› Verified 1 days ago
Vamsi Kiran Kodumuri, Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 258 S Chickasaw Trl Ste 203, Orlando, FL 32825 Phone: 407-303-6588 | |
Francoeur Cadet, D.O Internal Medicine Medicare: Medicare Enrolled Practice Location: 232 N Orange Blossom Trl, Orlando, FL 32805 Phone: 407-428-5751 Fax: 407-447-7245 | |
Andrija Vidic, D.O Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2415 N Orange Ave Ste 700, Orlando, FL 32804 Phone: 407-303-2474 Fax: 407-303-0680 | |
Zain Zamir, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 2501 N Orange Ave Ste 235, Orlando, FL 32804 Phone: 407-303-7169 | |
Dr. Arsenio R Rodriguez, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1745 N Mills Avenue, Orlando, FL 32803 Phone: 407-841-7151 Fax: 407-648-2259 | |
Dr. Maria R Flores, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 70 W Gore St, Suite 100, Orlando, FL 32806 Phone: 407-426-8484 Fax: 404-426-8575 |